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Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a complex thrombotic disorder with environ-
mental and genetic determinants. Although several genetic variants have been found associated with VTE, they explain a minor
proportion of VTE risk in cases. We undertook a meta-analysis of genome-wide association studies (GWASs) to identify additional
VTE susceptibility genes. Twelve GWASs totaling 7,507 VTE case subjects and 52,632 control subjects formed our discovery stage where
6,751,884 SNPs were tested for association with VTE. Nine loci reached the genome-wide significance level of 5 3 108 including six
already known to associate with VTE (ABO, F2, F5, F11, FGG, and PROCR) and three unsuspected loci. SNPs mapping to these latter
were selected for replication in three independent case-control studies totaling 3,009 VTE-affected individuals and 2,586 control
subjects. This strategy led to the identification and replication of two VTE-associated loci, TSPAN15 and SLC44A2, with lead risk alleles
associated with odds ratio for disease of 1.31 (p ¼ 1.67 3 1016) and 1.21 (p ¼ 2.753 1015), respectively. The lead SNP at the TSPAN15
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transfusion-related acute lung injury. We further showed that these two variants did not associate with known hemostatic plasma
markers. TSPAN15 and SLC44A2 do not belong to conventional pathways for thrombosis and have not been associated to other cardio-
vascular diseases nor related quantitative biomarkers. Our findings uncovered unexpected actors of VTE etiology and pave the way for
novel mechanistic concepts of VTE pathophysiology.Introduction
Venous thromboembolism (VTE [MIM 188050]) is a
common multicausal thrombotic disease with an annual
incidence of 1 per 1,000. It includes two main clinical
manifestations: deep vein thrombosis (DVT) and pulmo-
nary embolism (PE). The latter is associated with a
1-year mortality of 20%, making VTE the third leading
cause of cardiovascular death in industrialized coun-
tries.1 Moreover, among survivors, 25%–50% will have
lasting debilitating health problems such as post-throm-
botic syndrome, severely hampering mobility and quality
of life.
Factors contributing to VTE include endothelial injury
or activation, reduced blood flow, and hypercoagulability
of the blood, the so-called Virchow triad.2 Venous throm-
boembolism has a strong genetic basis that is character-
ized by an underlying heritability estimate of 50% and a
risk of developing the disease in an individual with an
affected sib 2.5 higher than for the general popula-
tion.3,4 But, like other complex phenotypes, most genetic
contributors have not been elucidated because the pro-
portion of heritability explained by replicated variants
has been small.5,6
There are seven well-established genetic risk factors
for VTE, all responsible for inherited hypercoagulable
states. The first three are heterozygous deficiencies of
the natural coagulation inhibitors (antithrombin, pro-
tein C, and protein S). These deficiencies are relatively
rare, affecting <1% of the general population, and they
increase VTE risk by approximately ten. The other
four, Factor V (FV [MIM 612309]) Leiden, prothrombin
(MIM 176930) G20210A, fibrinogen g’ (FGG) (MIM
134850) rs2066865, and blood group non-O, are more
frequent with prevalence in European-descent indi-
viduals around 5% for the former two and ~25% for
the latter two. The increase in VTE risk is about
3-fold for the FV Leiden (RefSeq accession number
NP_000121.2, p.Arg534Gln [c.1601G>A]) and prothrom-
bin G20210A (RefSeq NM_000506.3, c.*97G>A) muta-
tions, 2-fold for non-O blood group, and 1.5-fold for
FGG rs2066865.7
The genome-wide association strategy is a powerful
method to identify common SNPs associated with a com-
plex disorder without a pre-specified hypothesis. Although
previous genome-wide association studies (GWASs) have
been reported for VTE, none has included more than
1,961 case subjects5,6 and none has yielded new genetic
loci. In this article, we report the largest investigation to
date of the influence of common genetic variations on
VTE risk by meta-analyzing GWAS findings from 12
studies.The AmSubjects and Methods
Study Design
We report on a three-stage investigation of common genetic pre-
dictors of VTE. A discovery phase included 7,507 VTE case subjects
and 52,632 control subjects from 12 studies and a replication
phase included 3,009 case subjects and 2,586 control subjects
from three independent studies. In addition, confirmed discov-
eries were then examined for association with quantitative bio-
markers of VTE risk, gene expression in various tissues and cell
types, as well as with whole blood DNA methylation levels.Participants in Discovery and Replication
For the discovery phase, participants were European-ancestry
adults in two French case-control studies, two Dutch case-control
studies, and four cohort and four case-control studies from the
United States. Details of each study have been previously pub-
lished.8–19 Three other French case-control studies for VTE were
used for the replication stage.11,20 In all studies, VTE (PE or DVT)
was objectively diagnosed by physicians using different tech-
niques including compression venous duplex ultrasonography,
computed tomography, Doppler ultrasound, impedance plethys-
mography, magnetic resonance, venography, pulmonary angiog-
raphy, and ventilation/perfusion lung scan. VTE events related
to cancer, autoimmune disorders, or natural anticoagulant inhib-
itor deficiencies (protein C, protein S, antithrombin) were
excluded in most studies. A detailed description of the design
and the clinical characteristics of all VTE studies analyzed in this
work is presented in Table S1. All participating studies were
approved by their respective institutional review board and
informed consent was obtained from studied individuals.Genotyping and Imputation
Within each discovery study, DNA samples were genotyped with
high-density SNP arrays and were imputed for SNPs available in
the 1000 Genomes reference dataset. Summary descriptions of
genotyping technologies, quality-control procedures, and imputa-
tionmethods used for the discovery cohorts are shown in Table S1.
In the replication studies, genotyping of the selected SNPs was per-
formed by allele-specific PCR.Association Analyses and Meta-Analysis for Discovery
Association analyses of imputed SNPs with VTE risk were per-
formed separately in each study by using logistic or Cox-propor-
tional regression analyses adjusted for study-specific covariates
(Table S1). All SNPs with acceptable imputation quality (r2 >
0.3)21 in all 12 discovery studies and with estimated minor allele
frequency greater than 0.005 were entered into a meta-analysis.
For the meta-analysis, a fixed-effects model based on the inverse-
variance weighting was employed as implemented in the METAL
software.22 A statistical threshold of 5 3 108 controlling for the
number of independent tests across the genome was applied to
declare genome-wide significance.21,23,24 Heterogeneity of the
SNP associations across studies was tested with the Cochran’s Q
statistic and its magnitude expressed by the I2 index.erican Journal of Human Genetics 96, 532–542, April 2, 2015 533
Table 1. Main Findings at Loci Demonstrating Genome-wide Significant Association with VTE in the Discovery Cohorts
Lead SNP Chr. Gene Description
Discovery Stage (7,507 Case Subjects and
52,632 Control Subjects)
Replication Stage (3,009 Case
Subjects and 2,586 Control
Subjects) Combined
Risk
Allele
Risk Allele
Frequency Allelic ORa p
Risk Allele
Frequency Allelic OR p pb
Known Loci
rs6025 1 F5 missense T 0.033 3.25 (2.91–3.64) 1.10 3 1096 – – – –
rs4524c 1 F5 missense T 0.736 1.20 (1.14–1.26) 2.65 3 1011 – – – –
rs2066865 4 FGG 30 UTR A 0.244 1.24 (1.18–1.31) 1.03 3 1016 – – – –
rs4253417 4 F11 intronic C 0.405 1.27 (1.22–1.34) 1.21 3 1023 – – – –
rs529565 9 ABO intronic C 0.354 1.55 (1.48–1.63) 4.23 3 1075 – – – –
rs1799963 11 F2 intronic A 0.010 2.29 (1.75–2.99) 1.73 3 109 – – – –
rs6087685 20 PROCR intronic C 0.302 1.15 (1.10–1.21) 1.65 3 108 – – – –
New Loci
rs4602861 8 ZFPM2 intronic A 0.766 1.20 (1.13–1.27) 3.48 3 109 0.714 1.02 (0.94–
1.11)
0.631 5.04 3 107
rs78707713 10 TSPAN15 intronic T 0.878 1.28 (1.19–1.39) 5.74 3 1011 0.891 1.42 (1.24–
1.62)
2.21 3 107 1.67 3 1016
rs2288904d 19 SLC44A2 missense G 0.785 1.19 (1.12–1.26) 1.07 3 109 0.764 1.28 (1.16–
1.40)
2.64 3 107 2.75 3 1015
aAllelic odds ratio associated with the risk allele with its corresponding confidence interval. For ease of presentation, all confidence intervals shown in this table have
been computed at a ¼ 0.05.
bThe combined p value was derived from a fixed effect meta-analysis of the discovery and replication results.
cThe rs4524 was associated with VTE risk independently of the rs6025 variant.
dThe rs2288904 was not the lead SNP observed at the SLC44A2 locus. However, because it is a non-synonymous polymorphism with strong evidence for func-
tionality that is in strong LD (r2 ~ 1) with the lead intronic rs2360742 (p ¼ 5.6 3 1010), it was the one taken forward for replication.Association Analyses and Meta-Analysis for
Replication
In the replication cohorts, association of tested SNPs with VTE risk
was assessed by use of logistic regression under the assumption of
additive allele effects, adjusting for age and sex. Results obtained
in the replication cohorts were meta-analyzed via a fixed-effects
model based on the inverse-variance weighting as implemented
in the METAL software.22 A statistical threshold of 0.05 divided
by the number of replications performedwas used to declare statis-
tical replication. Heterogeneity of the SNP associations across
studies and subgroups of individuals (e.g., PE versus DVT) was
tested via the Cochran’s Q statistic and its magnitude expressed
by the I2 index. For replicated SNPs, meta-analyses of all
studies were performed to produce the most robust estimate of
the effect size.
Conditional Analysis to Discover Independent Signals
at Replicated Loci
To test for the presence of additional independent VTE-associated
SNPs at each of the replicated loci, we re-analyzed in each discov-
ery study a GWAS conditioning on the imputed allelic dose of each
replicated SNP and meta-analyzed the results by the same strategy
as the original GWAS analysis. Areas within 200 kb up- and down-
stream of the SNPs were examined.
Biologic Follow-up on Replicated Findings
The influence of replicated SNPs on the variability of hemostatic
traits known to associate with VTE pathophysiology andmeasured
in our available cohorts was assessed to learn more about biologic534 The American Journal of Human Genetics 96, 532–542, April 2, 2pathways. Investigated quantitative biomarkers were D-dimers,
endogenous thrombin generation, plasma antigen or activity
levels of fibrinogen, coagulation factors II, VII, VIII, IX, X, and
XII, von Willebrand factor, antithrombin, protein C, protein S
(total and free), protein Z, activated partial thromboplastin time,
hemoglobin, and white blood cell and platelet counts. Associa-
tions of replicated SNPs with these quantitative hemostatic traits
were investigated in five cohorts that were part of the discovery
and replication stages by using linear regression analyses adjusted
for age-, sex-, and cohort-specific covariates. The overall statistical
evidence for association with a given phenotype across available
cohorts was assessed by use of the Fisher combined test statistics
to account for differentmeasurementmethods used across studies.
Replicated SNPs were examined for association with the expres-
sion of their structural genes via publicly available genome-wide
gene expression data from multiple cell lines and tissues. Impact
of replicated lead SNPs onDNAmethylation levels from peripheral
blood DNA was also investigated.Results
After applying quality-control measures, 6,751,884 SNPs
were tested for association with VTE in a total of 7,507
case subjects and 52,632 control subjects. The Manhattan
and Q-Q plots of the meta-analysis of GWAS results are
shown in Figures S1–S4. A total of 1,060 SNPs clustered
into nine chromosomal regions and reached the genome-
wide significance level of p < 5 3 108.015
Table 2. Replication Findings for Three SNPs that Reached Genome-wide Significance in the Discovery GWAS
SLC44A2 rs2288904 TSPAN15 rs78707713 ZFPM2 rs4602861
GG GA AA TT TC CC AA AG GG
MARTHA12
Control subjects 468 (60%) 258 (33%) 58 (7%) 624 (80%) 146 (19%) 5 (1%) 409 (53%) 314 (40%) 56 (7%)
Case subjects 764 (64%) 391 (33%) 35 (3%) 1,025 (86%) 162 (13%) 7 (<1%) 629 (53%) 472 (39%) 92 (8%)
RAFa 0.762 versus 0.806 0.899 versus 0.926 0.727 versus 0.745
Allelic ORb 1.302 (1.115–1.519); p ¼ 8.67 3 104 1.428 (1.136–1.798); p ¼ 2.31 3 103 1.002 (0.866–1.157); p ¼ 0.986
FARIVE
Control subjects 339 (59%) 204 (35%) 32 (6%) 452 (79%) 114 (20%) 9 (1%) 284 (50%) 231 (40%) 60 (10%)
Case subjects 370 (64%) 189 (32%) 22 (4%) 478 (82%) 102 (18%) 1 (<1%) 289 (50%) 243 (42%) 48 (8%)
RAF 0.767 versus 0.799 0.885 versus 0.910 0.695 versus 0.708
Allelic OR 1.208 (0.989–1.475); p ¼ 0.064 1.317 (1.000–1.733); p ¼ 0.050 1.064 (0.891–1.271); p ¼ 0.495
EDITH
Control subjects 680 (58%) 422 (36%) 66 (6%) 921 (79%) 236 (20%) 14 (1%) 564 (49%) 487 (42%) 110 (9%)
Case subjects 739 (63%) 394 (34%) 30 (3%) 993 (85%) 172 (15%) 8 (<1%) 570 (49%) 478 (41%) 110 (10%)
RAF 0.763 versus 0.805 0.887 versus 0.920 0.695 versus 0.699
Allelic OR 1.294 (1.121–1.492); p ¼ 4.32 3 104 1.457 (1.197–1.776); p ¼ 1.76 3 104 1.014 (0.896–1.148); p ¼ 0.821
Combined allelic ORc 1.277 (1.164–1.403); p ¼ 2.64 3 107 1.416 (1.241–1.616); p ¼ 2.21 3 107 1.021 (0.939–1.110); p ¼ 0.631
aRisk allele frequencies in control subjects and in case subjects, respectively.
bAllelic odds ratio for disease associated with the risk allele of the studied polymorphisms derived from a logistic regression analysis adjusted for age and sex.
cCombined adjusted allelic OR derived from a standard fixed-effect meta-analysis of the results observed in the three replication studies. There was no evidence for
heterogeneity across the three replication studies for the association of rs2288904 (I2¼ 0.388, p¼ 0.823), rs78707713 (I2¼ 0.364, p¼ 0.833), or rs4602861 (I2¼
0.285, p ¼ 0.867) with the disease.Among the nine loci that were genome-wide significant
in the discovery scan, six were already known to be associ-
ated with VTE (ABO [MIM 110300], F2, F5, F11 [MIM
264900], FGG, and PROCR [MIM 600646]) whereas three
had not been previously reported to be associated with
VTE: TSPAN15 (MIM 613140), SLC44A2 (MIM 606106),
and ZFPM2 (MIM 603693) (Table 1). At loci with SNPs
known to be associated with VTE, we did not identify addi-
tional VTE associations with variants. Detailed descrip-
tions of findings at the known loci are in Figures S1 and S3.
For the three unknown loci, the region-specific lead
SNPs were all common intronic variants: rs78707713 in
TSPAN15 with risk allele frequency (RAF) 0.88 and associ-
ated odds ratio (OR) for VTE of 1.28 (p ¼ 5.74 3 1011),
rs2360742 in SLC44A2 with RAF ¼ 0.78 and OR ¼ 1.20
(p ¼ 5.59 3 1010), and rs4602861 in ZFPM2 with RAF ¼
0.77 and OR ¼ 1.20 (p ¼ 3.48 3 109). These associations
showed little heterogeneity across studies, with Cochran’s
Q¼ 16.8, I2¼ 0.34, p¼ 0.11 for TSPAN15 rs78707713. Cor-
responding values were Q ¼ 5.64, I2 ¼ 0.00, p ¼ 0.90 for
SLC44A2 rs2360742 and Q ¼ 15.2, I2 ¼ 0.28, p ¼ 0.17 for
ZFPM2 rs4602861. Of note, the intronic SLC44A2
rs2360742 was in complete association (r2 ¼ 1) with the
non-synonymous rs2288904 (p.Arg154Gln [c.461G>A])
that ranked ninth (in terms of p value) at this locus (p ¼
1.07 3 109). No coding SNPs in TSPAN15 or ZFPM2The Amwere in high linkage disequilibrium (LD) with their
lead SNPs.
We attempted replication of TSPAN15 rs78707713,
SLC44A2 rs2288904, and ZFPM2 rs4602861 SNPs in the
meta-analysis of three independent studies totaling 3,009
VTE-affected individuals and 2,586 control subjects. We
did not observe any evidence for association of ZFPM2
rs4602861 with VTE risk, overall or in any of the three
replication studies (Table 2), despite having 93% power
in the combined replication studies to detect at the 0.017
(¼0.05 / 3) statistical threshold the effect of a SNP with
RAF 0.76 and associated with an OR of 1.20.25 Conversely,
we confirmed association for TSPAN15 rs78707713 and
SLC44A2 rs2288904 SNPs (Table 2). In meta-analyzed
replication results, the common TSPAN15 rs78707713-T
allele was associated with an OR for VTE of 1.42 (p ¼
2.21 3 107) (Figure S5), and the common SLC44A2
rs2288904-G allele with an increased risk of 1.28 (p ¼
2.64 3 107) (Figure S6). When the results obtained in
the discovery and the replication studies were meta-
analyzed, the summary OR for VTE was 1.31 (p ¼ 1.67 3
1016) for TSPAN15 rs78707713 (Figure S5) and 1.21 (p ¼
2.75 3 1015) for SLC44A2 rs2288904 (Figure S6). No het-
erogeneity across the 15 studies was present: Q ¼ 18.6, I2¼
0.25, and p ¼ 0.18 for TSPAN15 rs78707713 and Q ¼ 7.40,
I2 ¼ 0.00, and p ¼ 0.92 for SLC44A2 rs2288904.erican Journal of Human Genetics 96, 532–542, April 2, 2015 535
Figure 1. Regional Association Plot at
the TSPAN15 Locus
Association results were derived from the
meta-analysis of 12 GWASs (top) that
were further conditioned on the effect of
TSPAN15 rs7870713 (bottom). SNPs are
colored according to their pairwise LD r2
with the lead rs7870713. r2 was estimated
from 1000 Genomes (Mar 2012 Eur)
database.Visual inspection of the regional association plots at the
TSPAN15 (Figure 1) and SLC44A2 (Figure 2) suggested that
all SNPs at these loci with high level of significance for
association with VTE were in strong LD with the lead
SNPs. This was confirmed by the results of the conditional
analysis that did not produce any other signal significant
at the 5 3 108 statistical threshold. After adjusting for
rs78707713, the lowest p value observed at TSPAN15 was
p¼ 4.923 104 for the intronic rs1072160 (Figure 1). Con-
ditioning on rs2288904 abolished all associations at the
SLC44A2 locus, the lowest p value then being p ¼ 0.047
for the KEAP1 rs45524632 (Figure 2).
In subgroup analyses of the replication studies, the geno-
type distribution of TSPAN15 rs78707713 and SLC44A2
rs2288904 did not differ according to the clinical manifes-
tations of VTE, either PE or DVT (Table S2). We did not
observe heterogeneity in the effects of the two SNPs ac-
cording to sex nor to F5 rs6025 or F2 rs1799963 mutations
(Tables S3 and S4).536 The American Journal of Human Genetics 96, 532–542, April 2, 2015Although the six known VTE-asso-
ciated loci affect VT risk through a
modulation of known hemostatic
traits (i.e., levels of von Willebrand
factor and Factor VIII for ABO, of
FXI for F11, of endogenous thrombin
potential for F2, of resistance to acti-
vated protein C for F5, of fibrinogen
for FGG, and of protein C for
PROCR26–33), the loci of the two
discovered genetic associations were
not in or near genes that are currently
known to influence hemostasis. We
then explored whether these SNPs
were associated with well-character-
ized hemostasis phenotypes that are
associated with thrombotic propen-
sity. We did not find any evidence
for an association with 25 plasma
biomarkers (Table S5) even though
the sample size of the investigated
studies were sufficiently statistically
powered (~95%) to detect the addi-
tive allele effect of any SNP that
would explain 1% of the variability
of a quantitative trait.34 By contrast,
the anticipated effects of the sixknown VTE-associated loci were observed in these studies
(Table S6).
We interrogated genome-wide gene expression in ten tis-
sues and DNA methylation studies in blood to determine
whether the TSPAN15 and SLC44A2 SNPs influenced the
regulation of their associated genes. We observed signifi-
cant associations of the TSPAN15 rs78707713 with
TSPAN15 DNA methylation measured from peripheral
blood DNA and TSPAN15 expression in macrophages,
endothelial cells, and esophagus mucosa (Table 3). The
SLC44A2 rs2288904 was found significantly associated
with SLC44A2 gene expression in monocytes, macro-
phages, and whole blood (Table 4). However, for none of
the interrogated bio-resources for gene expression or
DNA methylation levels did the identified disease-associ-
ated SNPs show the strongest locus-wide effects. Of note,
most SNPs that demonstrated the greatest influence on
gene regulation at the replicated loci showed weak or
null associations with VTE risk (Tables 3 and 4). Further
Figure 2. Regional Association Plot at
the SLC44A2 Locus
Association results were derived from the
meta-analysis of 12 GWASs (top) that
were further conditioned on the effect of
SLC44A2 rs2288904 (bottom). SNPs are
colored according to their pairwise LD r2
with the lead rs2288904. r2 was estimated
from 1000 Genomes (Mar 2012 Eur)
database.analyses revealed that the observed effects of TSPAN15
rs78707713 and SLC44A2 rs2288904 on gene expression
and DNA methylation were probably due to their linkage
disequilibrium with other regulatory variants with stron-
ger effects (data not shown).Discussion
By using data frommore than 7,000 case subjects andmore
than 50,000 control subjects, which represents a 4-fold in-
crease in the number of VTE events used in our discovery
effort compared with that used in the latest meta-analysis
of GWASs for VTE, we identified and then replicated
two associations for common variants in TSPAN15 and
SLC44A2. The strengths of the associations were modest
in size with ORs of 1.3 or less, but the statistical evidence
was robust in the discovery and replication stages. Further,
we observed that the variants were not associated withThe American Journal of Humandozens of hemostatic markers charac-
terizing the coagulation/fibrinolysis
balance. The identified VTE-associ-
ated SNPs map to genes that are not
in conventional pathways to throm-
bosis that have marked most of the
genetic associations to date, sug-
gesting that these genetic variants
represent novel biological pathways
leading to VTE.
The common T allele, with fre-
quency ~0.89, of the identified
TSPAN15 rs78707713 was associated
with an increased risk of 1.31-fold.
The TSPAN15 rs78707713 is intronic
and the interrogation of several gene
expression databases as well as the
application of prediction/annotation
tools46–48 did not suggest any regula-
tory elements supporting a functional
role of this SNP. It is likely that the
SNP is in strong LD with yet unidenti-
fied culprit variant(s). For instance,
rs78707713 is in strong LD (pairwise
r2 ¼ 0.89) with the intronic TSPAN15
rs17490626 predicted46,47 to map an
enhancer domain, the significanceof the VTE association of the latter SNP being p ¼ 3.74 3
1010. No association of TSPAN15-coding SNPs with VTE
risk was observed in the discovery meta-analysis (smallest
p value ¼ 0.49). TSPAN15 codes for tetraspanin 15, a mem-
ber of the tetraspanin superfamily that act as scaffolding
proteins, anchoring multiple proteins to the cell mem-
brane.49 Members of the tetraspanin family have roles in
cells that regulate hemostasis. TSPAN24 (CD151)-50 and
TSPAN32 (TSSC6)-51 deficient mice exhibit a bleeding
phenotype with impaired ‘‘outside-in’’ signaling through
aIIbb3, the major platelet integrin. CD63 (TSPAN30)
facilitates the release of von Willebrand factor (VWF)
from endothelial cell Weibel-Palade bodies through tran-
sient enhancement of fusion between the Weibel-Palade
body membrane and the plasma membrane,52 which
probably contributes to the leucocyte attachment to the
endothelium.53
The risk allele at the second identified locus, SLC44A2
rs2288904-G, was also common, with frequency ~0.77. ItGenetics 96, 532–542, April 2, 2015 537
Table 3. TSPAN15 SNPs Showing the Strongest Influence on TSPAN15 Gene Expression and DNA Methylation Levels in Various Human
Bio-resources and Their Relation with the TSPAN15 VTE-Associated rs78707713
Bio-resource Cell Type or Tissue
Interrogated
Bio-resources
Best cis eQTL/mQTL SNP rs78707713
r2 between
rs78707713
and Best rsIDarsID
eQTL/mQTL
p Value
VTE Association
p Value
eQTL/mQTL
p Value
B cells Fairfax et al.35 rs7897621 0.0053 0.267 0.129 0.001
endothelial cells Erbilgin et al.36 rs768498 6.87 3 1027 0.807 2.80 3 1011 0.180
esophagus mucosa GTEx Consortium37 rs28463525 2.2 3 1017 5.64 3 109 2.4 3 1016 0.841
heart, left ventricle GTEx Consortium37 rs10823376 5.9 3 109 0.911 NA 0.217
heart Folkersen et al.38 rs768498 9.25 3 1010 0.807 0.038b 0.180
intestine Kabakchiev and
Silverberg39
rs4565792 2.28 3 105 0.639 0.373 0.242
nerve-tibial Folkersen et al.38 rs34187097 5.8 3 1010 0.507 NA 0.000
Gene expression liver Folkersen et al.38 rs2084274 9.02 3 104 0.195 0.092b 0.011
liver Schadt et al.40 rs972570 3.16 3 1030 3.31 3 104 NA 0.196
macrophages Garnier et al.41 rs768498 1.85 3 1039 0.807 1.12 3 106 0.180
monocytes Fairfax et al.35 rs2812541 0.012 0.356 0.991 0.013
monocytes Garnier et al.41 rs10128334 8.05 3 103 0.867 0.978 0.004*
2 hr LPS-stimulated
monocytes
Fairfax et al.42 rs10823371 3.50 3 104 0.701 0.233 0.217
24 hr LPS-stimulated
monocytes
Fairfax et al.42 rs1052179 2.90 3 103 0.073 0.693 0.148
2 hr IFN-stimulated
monocytes
Fairfax et al.42 rs5030949 1.65 3 103 0.025 0.307 0.004
DNA methylation whole blood Dick et al.43 rs12416520 2.24 3 10187 0.035 3.53 3 1046 0.489
aPairwise r2 was derived from the SNAP database45 except for result noted with asterisk (*) where linkage disequilibrium was estimated from the MARTHA GWAS
imputed genotypes.
bIn the ASAP study, the rs12242391 served as a proxy (r2 ¼ 0.84) for rs78707713 that was not typed.was associated with a relative risk of 1.21 and is probably
the functional variant. Indeed, the observed risk allele
(G) codes for the Arg154 isoform of the choline trans-
porter-like protein 2 (CTL-2). CTL-2 has been associated
with several human diseases,54 including transfusion-
related acute lung injury (TRALI). TRALI is a life-threat-
ening complication of blood transfusion and the leading
cause of transfusion-associated mortality in developed
countries. Severe TRALI is due to antibodies in blood
components directed against the human neutrophil allo-
antigen-3a (HNA-3a), which is determined by the Arg154
isoform.55,56 Greinacher et al.55 found that alloantibodies
targeting CTL-2 lead to leucocyte activation and aggrega-
tion. Recently, human anti-HNA-3a antibodies were
shown to directly interact with endothelial CTL-2 to
disturb pulmonary endothelial barrier function that would
lead to severe TRALI.57 It might be that carrying the HNA-
3a antigen, determined by the Arg154 isoform, favors acti-
vation of leucocytes/neutrophils and endothelial cells in
some triggering circumstances.
We did not observe any difference in TSPAN15 and
SLC44A2 VTE-associated SNP allele frequencies between
DVT- and PE-affected individuals in the replication popula-538 The American Journal of Human Genetics 96, 532–542, April 2, 2tions, the two main clinical manifestations of VTE. This
observation suggests that the underlying pathophysiolog-
ical mechanisms are more likely to be involved in
thrombus formation rather than its rupture and its migra-
tion toward the pulmonary vein. About 20% of persons
with unprovoked VTE (i.e., occurring without clear
external factors like surgery, trauma, immobilization, hor-
mone use, or cancer) will experience a recurrent event,
even after a 6-month course of anticoagulant prophylaxis.
Because we had little information about recurrence follow-
up in our studies, we were not able to assess whether the
identified SNPs can discriminate between individuals
that will and those that will not face a recurrent event.
Investigating whether these SNPs can help improve the
secondary prevention of VTE would definitively be
warranted.
Despite having gathered the largest GWAS samples of
VTE-affected individuals, our approach was not well
powered to identify common SNPs associated with more
modest effects than those observed for SLC44A2 and
TSPAN15, i.e., with OR< 1.20, or extremely rare mutations
(e.g.,with frequency<1%) that cannotbe efficiently tagged
by the tested SNPs (Table S7). Heterogeneity in the design015
Table 4. SLC44A2 SNPs Showing the Strongest Influence on SLC44A2 Gene Expression in Various Human Bio-resources and Their Relation
with the SLC44A2 VTE-Associated rs2288904
Cell Type or Tissue
Interrogated
Bio-resources
Best cis eQTL SNP rs2288904
R2 between
rs2288904
and Best eSNParsID eQTL p Value
VTE Association
p Value eQTL p Value
B cells Fairfax et al.35 rs8106664 3.99 3 104 6.12 3 109 2.72 3 103 0.906
Heart Folkersen et al.38 rs3760648 8.59 3 104 0.293 0.868 0.000
Intestine Kabakchiev and
Silverberg39
rs11672431 5.71 3 105 9.70 3 103 0.050 0.116
Liver Schadt et al.40 rs7251213 4.01 3 106 3.57 3 103 NA 0.160
Liver Folkersen et al.38 rs11672431 5.29 3 104 9.70 3 103 0.115 0.116
Macrophages Garnier et al.41 rs3859514 1.92 3 1012 1.34 3 104 1.36 3 109 0.393
Monocytes Garnier et al.41 rs62129987 4.85 3 1025 1.64 3 105 2.71 3 1012 0.440*
Monocytes Fairfax et al.35 rs7252007 7.39 3 1030 6.98 3 103 5.01 3 109 0.345
24 hr LPS-stimulated monocytes Fairfax et al.42 rs7252007 4.03 3 1010 8.47 3 105
2 hr LPS-stimulated monocytes Fairfax et al.42 rs7252007 1.06 3 105 4.70 3 104
2 hr IFN-stimulated monocytes Fairfax et al.42 rs12609501 1.92 3 1012 9.23 3 103 1.57 3 107 0.072
Whole blood Westra et al.44 rs892078 3.64 3 1093 2.11 3 105 3.85 3 1070 0.438
Of note, no CpG probe targeting the SLC44A2 locus satisfied the adopted quality-control procedures, preventing us from efficiently testing for the effect of
SLC44A2 rs2288904 on DNA methylation levels at this locus in the interrogated bio-resources.
aPairwise r2 was derived from the SNAP database45 except for result noted with asterisk (*) where linkage disequilibrium was estimated from the MARTHA GWAS
imputed genotypes.and clinical characteristics of the studied populations
might also have contributed to slightly attenuate the power
of our study to detect additional genome-wide significant
associations. Further investigations deserve to be con-
ducted to better characterize the 202 suggestive statistical
associations with p < 105 in our discovery meta-analysis
and to identify additional susceptibility loci for VTE.
Though additional work is needed, including the identi-
fication of the functional TSPAN15 variant(s), our results
demonstrated that SLC44A2 and TSPAN15 are two suscep-
tibility loci for VTE. The products of the two genes, ex-
pressed by cells that are central to the pathophysiology
of thrombosis (monocytes/macrophages and endothelial
cells), are not known to have central roles in the traditional
hemostasis pathways nor to other cardiovascular diseases.
These results pave the way for novel mechanistic concepts
of VTE pathophysiology, new biomarkers for the disease,
and novel therapeutic perspectives.Supplemental Data
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